Protocol Ledger

NCT03435848 · Phase II · COMPLETED

Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy

Interventional Phase II clinical trial protocol NCT03435848 sponsored by BioSight in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-14 Enrollment: 66 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03435848
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)66 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03435848
Protocol FieldVerified Registry Value
NCT IdentifierNCT03435848
Consolidated Lead SponsorBioSight
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment66 participants (ACTUAL)
Registered Start Date2018-08-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI